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KAJIAN IN VITRO DAN IN VIVO FORMULASI LIPOSOM EKSTRAK 





Dalam kajian ini, potensi anti-angiogenik dan anti-tumor ekstrak terpiawai 
50% etanol daun Orthosiphon stamineus yang telah diseragamkan dinilai secara in 
vitro dan in vivo atas kanser paru-paru manusia. Sistem penyampaian ubat liposomal 
dihasilkan dari ekstrak ini bagi memperbaikikan bioketersediaan, efikasi, kestabilan 
dan profil keselamatan ekstrak. Tiga formulasi telah dihasil berdasarkan ekstrak ini: 
ekstrak nisbah ―phospholipid‖, ―phospholipid‖ dan kandungan kolesterol. NP2, iaitu 
formulasi yang mengandungi nisbah 1:1 ekstrak kepada ―phosphatidylcholine‖ 
dengan 20% kolesterol, telah menunjukkan kecekapannya dalam pemerangkapan, 
integriti, kestabilan dan efikasi liposom yang optimum.  
Liposom dianalisasi secara kualitatif dan kuantitatif dengan menggunakan mikroskop 
cahaya, TEM dan SEM, penyebaran cahaya dinamik (yang telah menunjukkan 
formasi vesikel nano berbentuk sfera yang utuh dengan permukaan yang licin dan 
membran dwilapisan yang tertutup sepenuhnya), ―zetasizer‖ dan potensi zeta (yang 
melaporkan vesikel anion nano dengan diameter dinamik 125 – 132 nm). NP2 telah 
menunjukkan sifat penghantaran sebatian bioaktif menonjol dan profil kestabilan 
yang terbaik apabila dibandingkan dengan ekstrak-ekstrak lain yang diuji selama 
enam bulan (P≤0.05), pada suhu 30ºC atau lebih rendah. Ekstrak ini dan liposom 
menghalang proliferasi sel kanser adenokarsinoma manusia (A549) dan sel 
endotelium normal manusia (EA.hy926), serta memaprakan potensi anti-angiogenik 




TEM ke atas sel A549 telah menunjukkan perubahan-perubahan morfologi 
―apoptotic‖ yang ketara, menunjukkan pengambilan liposom oleh sel-sel. Ekstrak ini 
juga menghalang pengkolonian ―in vitro‖, pencerobohan sel-sel dan penghijrahan sel 
melalui kebergantungan dos-masa. Kajian ―protein array‖ dan ―dual-luciferase‖ 
menunjukkan lebihan expresi pelbagai protein yang mengawal apoptosis, termasuk 
TGF-β dan MAPK / ERK, TRAILR-1, Bid, Bax, caspase 3, IGFBP-1 dan IGFBP-5; 
serta memperturunkan regulasi beberapa laluan-laluan lain seperti WNT, Bcl-2, 
cIAP-2, livin, IGFBP-3, IGFBP-6 dan IGF-1SR. Ekstrak ini dan NP2 merencatkan 
kolonisasi, penghijrahan dan pembentukan tiub sel-sel EA.hy926, serta menurunkan 
ekspresi VEGF dan HIF-1α yang mengakibatkan aktiviti angiogenesis. Data kajian in 
vivo keberkesanan ekstrak ini dan formulasi NP2 didedahka sebagai ejen anti-tumor 
yang kuat ke atas kanser paru-paru manusia menerusi model tumor xenograft serta 
pengaktifan ekspresi VEGF. Kajian farmakokinetik menunjukkan liposom 
meningkatkan bioavailabiliti oral dan peningkatan profil farmakokinetik. Kajian 
toksik ―acute‖ dan ―sub-acute‖ menunjukkan margin keselamatan yang baik untuk 
formulasi NP2. Liposom (NP2) menunjukkan efisiensi yang lebih baik secara 
signifikan dari segi peningkatan ―bioavailability‖ dan kestabilan berbanding dengan 
ekstrak yang tidak diformulasikan (E) (P≤0.05). Kesimpulannya, hasil kajian ini 
menunjukkan ekstrak O.S mempunyai aktiviti anti-tumor yang poten terhadap 
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In this study, anti-angiogenic and anti-tumour potencies of the standardized 
50% ethanol extract of Orthosiphon stamineus leaves (O.S extract) were assessed 
towards human lung cancer in vitro and in vivo. Liposomal drug delivery system was 
developed from the O.S extract to improve bioavailability, efficacy, stability and 
safety profiles of the O.S extract. Three formulation was developed based on the 
extract : phospholipid ratio, phospholipid and cholesterol content. NP2, which is a 
formulation consisting of 1:1 extract to phosphatidylcholine ratio with 20% 
cholesterol, showed optimum entrapment efficiency, integrity, stability and efficacy 
of the liposomes. Liposomes were characterized qualitatively and quantitatively 
using light, TEM and SEM microscopy (which shows intact formation of nano-
spherical shaped vesicles with mostly smooth surface and completely closed bilayer 
membrane), zetasizer and zeta potential (which reports anionic nano-vesicles with 
dynamic diameter 125-132 nm). NP2 shown significantly better release properties of 
the bioactive compounds and good stability profile than the O.S extract for six 
months stability studies (P≤0.05) at 30ºC or below. The O.S extract and the 
liposomes partially inhibited proliferation of human lung adenocarcinoma (A549) 
and human normal endothelial cells (EA.hy926), and revealed potent anti-angiogenic 
potency as in ex vivo assay of rat aortic ring. TEM analysis of A549 cells shows 
obvious apoptotic morphological alterations, with indication of the cellular uptake of 




in a dose–time dependent manner. Protein array and dual-luciferase studies show 
overexpression of various apoptotic-regulating proteins, including TGF-β and 
MAPK/ERK, TRAILR-1, Bid, Bax, caspase 3, IGFBP-1 and IGFBP-5; and down-
regulation of some other pathways, such as WNT, Bcl-2, cIAP-2, livin, IGFBP-3, 
IGFBP-6 and IGF-1SR. The O.S extract and NP2 inhibited EA.hy926 cells 
colonization, migration and tube formation, and also down-regulated the expression 
of VEGF and HIF-1α indicating anti-angiogenic activity. In vivo studies reveal 
potent anti-tumour activity of the O.S extract and the NP2 liposome formulation 
towards human lung cancer in xenograft tumour model and decreased VEGF 
expression. Pharmacokinetic studies show that the liposomes increased oral 
bioavailability and improved pharmacokinetic profile. Acute and sub-acute toxicity 
studies reveal good margin of safety for the NP2 formulation. The liposomes (NP2) 
show significantly better efficiencies with enhanced bioavailability and stability 
compared to the non-formulated O.S extract (E) (P≤0.05). All-in-all, the results of 
this study indicates that the O.S extract has potent anti-tumour activity towards lung 




CHAPTER 1 INTRODUCTION 
 
1.1 Cancer: 
1.1.1 Overview of Cancer: 
Cancer is an ambiguous disease, characterized by immortality of the cells and 
excessive proliferation frequencies, which might be related to an uncontrolled 
genetic mutation. There are two types of immortal cells; hyperplasia (normal cells) 
which is benign; and dysplasia (abnormal cells) which is malignant and can cause 
tumour development (Yarbro et al. 2011). Tumours might still at the tissues of origin 
or undergo metastases processes. Metastases is the invasion of the cancer cells from 
the original tissues into the neighbouring tissues where they form new tumours 
(Shevde and Welch 2003). 
1.1.2 Cancer Epidemiology: 
Cancer is one of the most public health problems worldwide. It is the main 
cause of many deaths, where one in every four deaths is related to cancer in the 
United States of America  (Siegel et al. 2014). Globally, there is an estimation of 
14.1 million new cancer cases with 8.2 million deaths annually of 27 different cancer 
types (Torre et al. 2015). 
Cancer incidences increase with the increase of the aging population which 
presence and the prevalence of risk factors. Less developed countries account more 
than 55% of cancer incidences with about 65% of deaths from cancers worldwide. 
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This might due to prevalence variations of risk factors, life styles, lower levels of 
health expenditure, detection tests, availability of treatment and education. Cancer 
incidences and mortalities attack males at a higher rate more than females (Igene 
2008; Ferlay et al. 2010; Jemal et al. 2011; Torre et al. 2015). Annually, more than 
3.5 million cancer cases have been recorded in Eastern Asia (Ferlay et al. 2010). 
Lung cancer is the leading cause of cancer mortality among males and a 
second leading cause of cancer death among women worldwide; breast cancer is the 
leading cause of cancer mortality among females worldwide. The other most 
common cancers recorded in males are prostate, colon, pancreas and liver 
respectively; while in females the most commonly reported cancers are lung, colon, 
pancreas and ovary (Ferlay et al. 2010; Siegel et al. 2014; Torre et al. 2015; Torre et 
al. 2016). 
Lung cancer represents 12.7% of the total cancer incidents. It is also the most 
serious and fatal cancer, with a fatality percentage of about 18% among all deaths 
from cancers globally. It is estimated that around 1.6 million lung cancer deaths and 
about 1.8 million new lung cancer cases occurs annually worldwide,  (Igene 2008; 
Ferlay et al. 2010; Torre et al. 2016). 
Cancer can be prevented by applications of various effective methods, 
including controlling of tobacco smocking, vaccination and early detection (Jemal et 




1.1.3 Causes and Risk Factors of Cancer: 
Environmental carcinogens play pivotal role in cancer incidences. They can 
cause genetic mutation that may enhance abnormal cell proliferations. The risk of the 
disease proportionally increases with exposure durations and the type of the 
environmental factors. Environmental carcinogens include many factors such as 
tobacco smocking, obesity, diet, sun rays, radiation, pathogens (Helicobacter pylori, 
papilloma viruses and hepatitis B or C virus among others) and some chemical 
agents (such as asbestos, industrial waste and pesticides) (Wang and Chen 2001). 
Some hormones significantly induce the development of some cancers such as 
those in prostate and breast cancers which are influenced by testosterone and 
oestrogen (Cuzick 2008). Lifestyle, race, aging, sex, sexual activity, heredity, 
pregnancy and physiological stress also participate in cancer occurrence (Kintzios 
and Barberaki 2004). Genetics play a crucial role in cancer control. There are two 
types of genes: proto-oncogenes (which stimulate tumour development) and tumour 
suppressor genes (which block the mechanism of cell division and prevent tumour 
development) (Kintzios and Barberaki 2004; Weeraratna 2005). 
1.1.4 Classification of Cancer Types: 
Cancer types can be classified according to various aspects as the following: 
1.1.4(a) Origin Tissue of Tumour: 
Cancer can be classified into three types, including carcinoma (if the tumour 
originates in epithelial cells); sarcoma (if the tumour emerges in the connective 
tissue) and glioma (if the tumour grows in non-neuronal brain cells). Carcinoma is 
the most common type (Yarbro et al. 2011). 
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1.1.4(b) Target Organs of Tumours: 
Cancer attacks various organs of the body with different prevalence 
percentages. The most common type of cancers nowadays is lung cancer. Other 
cancer types include breast, colorectal, bladder, kidney, lymphoma, leukaemia, 
ovarian, prostate, stomach,  skin pancreatic, and uterine cancers (Kintzios and 
Barberaki 2004). 
1.1.5 Genetic and Molecular Control of Cancer: 
Genetics control of cancer is developed via two basic types of mutations of 
some selected proteins; the first mutation leads to increment of activity of the 
proteins (the hyper-activated gene is known as oncogene), the other type of mutation 
resulted in inhibition of the activity of the proteins (the in-activated gene is known as 
tumour suppressor gene) (Kintzios and Barberaki 2004; Weeraratna 2005). 
Oncogenes participate in signalling pathways that induce cell proliferation, 
whereas suppressor genes involved in proteins that act normally as checkpoints to 
cell proliferation. Carcinogenic agents (such as radiation, chemicals or viruses) can 
induce genetic mutations (somatic mutations). Mutation might be also inherited 
(germ-line mutation) (Bertram 2000; Croce 2008; Yarbro et al. 2011). 
Hyper-activation or inactivation of many genetic pathways plays a crucial role 
in converting normal human cells into cancerous cells (Hanahan and Weinberg 
2000). Activation of oncogenes family of transmembrane tyrosine kinase receptors, 
named human epidermal growth factor receptor (EGFR), enhances cancer initiation. 
It includes four transmembrane glycoproteins (HER1/Erb-B1, HER2/neu/Erb-B2, 
HER3/Erb-B3 and HER4/Erb-B4) (Cohen and Carpenter 1975; Scaltriti and Baselga 
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2006). Over expression of telomerase enzyme enhances cell proliferation (Holt and 
Shay 1999). Many genes related to cancer development are depicted in table 1.1. 
Table 1.1 Genes involved in carcinogenesis (Kintzios and Barberaki 2004; 
Weeraratna 2005). 
Oncogenes Sites of cancer 
Tumour 
Sites of cancer suppressor 
genes 
Bcl-1 Breast, head and neck APC Colon and stomach 
BCR-ABL Leukaemia BRCA1 Breast and ovarian 
c-myc Lung, leukaemia,  BRCA2 Breast 
 stomach and breast CDK4 Skin 
CDKN2 Melanoma DPC4 Pancreas 
Erb-B Glioblastoma and breast MSH2, MSH6  Colon 
HPC1 Prostate and MLH1  
Ki-ras Lung, ovarian, colon p53 Various 
 and pancreatic  RB Retinoblastoma, bone, 
MDM2 Sarcomas  bladder, lung 
N-myc Neuroblastoma and   and breast 
 glioblastoma  VHL Kidney 
N-ras Leukaemia   
PDGF Glioma   
RET Thyroid   
 
1.1.6 Cancer Angiogenesis: 
Since 1970s, many studies had been carried out to improve cancer treatment 
strategies, by targeting tumour vasculature by disrupting various steps of 
neovascularization development. Growth process of new blood vessels from the 
existing vascular bed is commonly known as angiogenesis. This is a complex process 
that controls normal physiological development of new blood vessels, placental 
development during pregnancy, wound healing processes and for menstruation cycle 
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through series of processes, including endothelial cell proliferation, migration as well 
as tube formation cascades (Folkman 1971; Charnley et al. 2008; Ahmed and 
Bicknell 2009). Unregulated angiogenesis contributes in development of some 
pathological conditions, such as cancer (tumour growth), psoriasis, obesity and 
diabetic retinopathy. For tumour growth up to larger than one mm
3
, it requires more 
supplementation with oxygen and nutrients. Therefore, new blood vessels are 
developed to connect these supplies into the tumour. Diminishing development of 
new blood vessels leads to starvation of the tumour cells and less chance for tumour 
to survive. The angiogenesis process also plays a pivotal role in metastasis of cancer 
cells to other localities (Folkman 1985; Tonini et al. 2003; Eskens 2004). 
1.1.6(a) Regulation of Angiogenesis via VEGF: 
Vascular endothelial growth factor (VEGF), pro-angiogenic mitogens, has 
been described in the past as vascular permeability factor (VPF), which regulates 
microvascular leakage (Senger et al. 1990). VEGF family includes various pivotal 
factors that control blood, nervous and lymphatic systems during embryonic 
development and processes of wound healing. Even in adults, VEGFs still participate 
partially in conserving vessels homeostasis (Ahmed and Bicknell 2009). 
VEGFs regulate neovascularization related to some pathological changes and 
illnesses such as cancer (Olsson et al. 2006). Hypoxia-inducible factor-1 (HIF-1) 
strongly stimulates VEGF expression. In addition, some oncogenes that activate HIF-
1 expression stimulate VEGF transcription; this induces tumour angiogenesis 
pathways (Shweiki et al. 1992; Ahmed and Bicknell 2009). 
There are many identified members of VEGF family, including VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor (PlGF). On the 
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other hand, there are selected tyrosine kinase receptors (VEGFRs), such as VEGFR-
1, VEGFR-2 and VEGFR-3. Various studies have revealed that VEGF-A controls 
development of blood vessel and angiogenesis by binding abilities with VEGFR-1 
and VEGFR-2 receptors. Activation of VEGF-C and VEGF-D is regulated by their 
binding with VEGFR-2 and VEGFR-3 for initiation of vascularization and 
controlling of the lymphatic system. VEGF-E binds only to VEGFR-2 in viruses 
selectively (Fong et al. 1995; Ferrara 2001; Ahmed and Bicknell 2009). There are 
different isoforms of VEGF-A have been identified, including VEGF121, VEGF145, 
VEGF148, VEGF165, VEGF183, VEGF189 and VEGF206 (Niu and Chen 2010). 
A binding of VEGF to VEGFR-2 receptor through kinase domains signalling 
pathway mediates various processes, including endothelial cell proliferation, 
differentiation, migration and survival activities. VEGFs stimulate phosphorylation 
of tyrosine residues, which has resulted in controlling of the signals of VEGFR-2. 
There are four autophosphorylayion sites, recognized by VEGFs, including 
tyrosine‘s 951, 996, 1054 and 1059 (Dougher and Terman 1999; Takahashi et al. 
2001; Zeng et al. 2001; Jussila and Alitalo 2002). 
Transphosphatidylation reaction of VEGF activates a mediatory enzyme 
(phospholipase D) that controls angiogenesis phenotype. This activation depends on 
tyrosine phosphorylation and protein kinase C. It regulates many processes that 
initiate angiogenesis pathways (such as endothelial cell migration) (Seymour et al. 
1996). VEGF also activates nitric oxide (NO) synthase and stimulates nitric oxide 
production by a mediation of VEGFR; this augments controlling of sprouting of new 
blood vessels and potentiates endothelial cell proliferation and migration (Ziche et al. 
1997; Garcia-Cardena et al. 1998). 
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1.1.6(b) Role of Hypoxia in Angiogenesis Pathway: 
Invasion and metastasis are two interrelated processes, required for tumour 
growth. Tumour development is significantly controlled by an ‗‗angiogenic switch‘‘ 
through balance between the proangiogenic and anti-angiogenic factors. Hypoxia is a 
common proangiogenic factor (Folkman 2002). Various environmental and 
epigenetic influences also control neovascularization of tumour and metastases (such 
as acidosis, hypoxia and hypoglycaemia (Ahmed and Bicknell 2009). 
Hypoxia is the situation of diminution of oxygen supply which stimulates 
tumour growth. Hypoxia is mediated by transcription factors known as hypoxia-
inducible factors (HIFs). Hypoxia-inducible factor 1 (HIF-1) is the major one of 
HIFs. Structure of HIF-1 includes two DNA-binding proteins (heterodimer), HIF-1α 
and HIF-1β (aryl hydrocarbon nuclear translocator (ARNT)) (Charnley et al. 2008; 
Ahmed and Bicknell 2009). 
There are another two HIFs: HIF-2α and HIF-3α, which control angiogenesis 
in addition to HIF-1α. HIF-2α has lesser participations in adult and tumour 
angiogenesis than the other two (i.e. HIF-1α and HIF-3α); but it plays a vital role in 
embryonic development (Leek et al. 2002). 
Hypoxia activates genetic expression of VEGF (Shweiki et al. 1992). There 
are many other extra-cellular pathways that participate in regulating hypoxia induced 
angiogenesis, such as notch/delta, ephrin/Eph receptor, netrins/UNCs, 
roundabouts/slits, endothelins-1 and 2, adrenomedullin, semaphorins, angiogenin, 
neuropillins, plexins and various intracellular protein families (hedgehog and sprout) 
(Pilch et al. 2001; Bicknell and Harris 2004; Ahmed and Bicknell 2009). 
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In addition, hypoxia controls many other angiogenic pathways, including 
inducible endoplasmic reticulum oxygen-regulated protein-150 (ORP-150), which is 
induced as a VEGF chaperone (Ozawa et al. 2001); leptin gene up-regulated by HIF-
1 (Ambrosini et al. 2002); and connective tissue growth factor (CTGF), which is a 
potent angiogenic factor in human breast cancer cells (Shimo et al. 2001). 
Furthermore, HIF-1α regulates stromal cell-derived factor-1 (CXCL12), which leads 
to induction of VEGF expression and up-regulation of migratory inhibitory factor 
(MIF) (Hitchon et al. 2002; Bacher et al. 2003). Likewise, hypoxia hyper-activates 
the expression of placenta growth factor (PlGF) (Green et al. 2001), and many other 
polypeptide angiogenic factors, including some metabolites of glycolysis (such as 
pyruvate and lactate) (Murray and Wilson 2001). Angiopoietins are a family of cell-
specific molecules (Ang-1, 2, 3 and 4) which activate angiogenesis process via 
binding to Tie receptors (Makrilia et al. 2009). 
At normal conditions of oxygen supply, HIF-1α binds to E3 ubiquitin ligase 
which contains the Von Hippel-Lindau tumour suppressor protein (pVHL); this 
enhances an enzymatic proline-hydroxylation, co-activated in the presence of iron, 
which resulted in proteasomal degradation of HIF-1α (Ivan et al. 2001). Once the 
oxygen tension decreases up to less than 2% (due tumour growth), then, the cancer 
cells protect the degradation of HIF-1α to maintain tumour survival even under 
hypoxic situation. HIF-1α resists the degradation and accumulates in the nucleus, 
followed by formation of a complex by ligation with HIF-1β and transcriptional co-
activators (CBP/p300). This results in induction of selected genes that have hypoxia 
response elements (HREs). These genes include VEGF, proteases enzymes (matrix 
metalloproteinase (such as MMP9)), proteins involved in invasion (urokinase 
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receptor and plasminogen activator-1) and proteins involved in glycolytic pathway 
(Harris 2002; Wenger 2002). 
Reactive oxygen species (ROS) also control signalling pathways of various 
cellular functions (such as angiogenesis and tumour growth) (Ushio-Fukai and 
Alexander 2005; Xia et al. 2007). Various studies had reported that the 
endogenous H2O2 (converted to OH- via Fenton reaction) stimulated expression of 
VEGF (Ruef et al. 1997). H2O2 can also induce many steps of angiogenesis cascades, 
including endothelial cell proliferation and migration (Yasuda et al. 1999). It also 
stimulates microtubules morphogenesis (Shono et al. 1996). Hypoxia produces ROS, 
which has resulted in induction of various angiogenesis processes, including tube 
formation (Lelkes et al. 1998). Anti-oxidant activity results in a potent scavenging of 
ROS, this might support anti-angiogenic mechanism (Xia et al. 2007). 
Nowadays, there are many anti-angiogenic agents, which have been approved 
for treating cancers. These drugs are used as adjuvants to chemotherapy regimens 
such as the combination of the anti-angiogenic agent bevacizumab with the 
chemotherapeutic agent paclitaxel and/or carboplatin, which augmented their 
efficiency in lung cancer therapy. Other recently developed anti-angiogenic agents 
include axitinib, aflibercept, brivanib, nintedanib, cediranib, pazopanib, sorafenib, 
ramucirumab, sunitinib, imatinib and vatalanib (Sandler et al. 2005; George and 




The ultimate goal of all strategies of cancer treatment is to enhance the death 
of cancer cells via induction of apoptotic cascades. Apoptosis, programmed cell 
death, is a strictly controlled and energy-dependent cell death process, which is not 
involved in necrosis or inflammation. It is a slow process but it can be induced by 
various internal or external causes that participate in regulation of normal or 
abnormal cell death. Induction of apoptosis is accompanied with activation of 
caspases; this has resulted in cell membrane becoming blebbing and condensation of 
nuclear chromatin, which consequently lead to a shrinkage of cells, losses of 
mitochondrial membrane permeability, formation of apoptotic bodies and finally 
phagocytosis of the cell debris (O'Driscoll et al. 2006; Elmore 2007; He et al. 2014). 
Necrosis, uncontrolled cell deaths, is different from apoptotic cells. It is 
characterised by some alterations of cellular morphology, including cytoplasmic 
swelling, rupture of plasma membrane and cytoplasmic organelles dilatation. This 
brings to excessive cell death and inflammation of the surrounded area. The necrotic 
cells are partially eliminated by phagocytosis (internalization mechanisms). Necrotic 
cell death plays a vital role in development of embryonic and adult tissues (Kroemer 
et al. 2005; Krysko et al. 2006; Golstein and Kroemer 2007). 
Necroptosis, another mechanism of controlled cell death, refers to the process 
of co-regulation of apoptosis and necrosis. Some studies revealed that necrosis could 
be controlled by a complex mechanism (Galluzzi and Kroemer 2008; Gunther et al. 
2012). 
Some studies have highlighted some events in this respect. Necrotic processes 
can be controlled by some genetic factors and specific receptors (Golstein and 
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Kroemer 2007). In addition, inactivation of caspases may be resulted in mixed 
processes of apoptosis and necrosis (Galluzzi and Kroemer 2008; Rosenbaum et al. 
2010). 
Necroptosis also can be regulated by many other factors, including 
necrostatins (Degterev et al. 2005), serine/threonine kinase activity (Kroemer et al. 
2009), necrotic inducing factor (NIF), apoptosis-inducing factor (AIF), RIP1, 
cyclophilin-D, and poly(ADP-ribose) polymerase-1 (PARP-1) (Galluzzi and 
Kroemer 2008). 
1.2.1 Apoptosis in Health and Diseases: 
Normally, apoptosis equilibrium plays a pivotal role in the development of the 
body, such as in the development of placenta during pregnancy (Sharp et al. 2010). 
Balance between apoptosis and cell proliferation processes augments the efficiency 
of the autoimmune system to control various diseases (such as rheumatoid arthritis) 
(Eguchi 2001). 
Cancer develops when the balance of the apoptotic processes is uncontrolled, 
leading to excessive immortal cells and induced cell proliferation. On the contrary, 
excessive apoptosis causes neurodegenerative diseases, such as Parkinson and 
Alzheimer disorders (Schiffer 2006; Srivastava 2007). 
1.2.2 Apoptosis Pathways: 
There are various characteristic alterations occurring in cells during apoptotic 
cell death, due to the presence of specific signals. Apoptosis can be enhanced 
through various pathways by proteins that play important roles in controlling cell 
cycle mechanism, including Wnt, Notch, hypoxia, NF-қB, p53 and MAPKs 
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pathways. Any deregulation in these apoptotic pathways can result in many 
malignancies (Kaufmann and Hengartner 2001; Ghobrial et al. 2005). 
Apoptotic signalling pathways are divided into two major types depending on 
the mechanism of initiation, extrinsic and intrinsic pathways. The extrinsic pathway 
is activated via cell death receptors, while the intrinsic pathway depends on 
mitochondrial changes. There are some other molecules that also incorporate with 
the mechanism of both extrinsic and intrinsic signalling pathways of apoptosis 
(Ghobrial et al. 2005). 
Caspases (cysteine aspartic acid-specific proteases) are a family of enzymes 
that play an essential role in cell apoptosis process. Caspases are activated at the 
early apoptotic steps (Eguchi 2001), leading to hyper-activation of some other factors 
of apoptosis (Kass et al. 1996). Caspases are produced in the cells as proenzymes 
(procaspases) as inactive forms of two subunits in which they are activated by 
apoptotic inducing factors (Substrates) (Guy S 2003). There are at least 14 known 
caspases in human cells. They are sub-grouped depending on their activities into 
three classes namely apoptosis activators, apoptosis executioners and inflammatory 
mediators. Apoptosis activators (initiator or upstream caspases) initiate the 
proteolytic processes; they include caspases 2, 8, 9 and 10. Apoptosis executioners 
(effector or downstream caspases) control cleaving of polypeptides (proteolysis) and 
disassembling the cells, including caspases 3, 6 and 7. Inflammatory mediators 
activate pro-inflammatory factors (such as cytokine), including caspases 1, 4, 5, 11, 
12, 13 and 14 (Lamkanfi et al. 2002; Guy S 2003; Fan et al. 2005). 
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1.2.2(a) Extrinsic Apoptotic Pathway: 
Extrinsic apoptotic pathway is also known as death receptor-mediated 
apoptotic pathway. Recently, studies had shown that the extrinsic pathway was 
initiated through binding of some inducing ligands with the death receptors (the most 
prominent ligands include CD95 (Fas), DR3, DR4, DR5 and DR6), produced 
ceramides, clustering (trimerization) of death receptors, followed by ligation of the 
adaptor molecule (FADD) with the cytoplasmic domain of the receptor. Then, FADD 
activates caspase 8, which subsequently cleaved procaspases 3 and 7. This had 
resulted in induction of apoptotic signalling pathway. Stimulation of tumour necrosis 
factor (TNF) receptors also conducted with the induction of apoptosis. In which, the 
binding of tumour necrosis factor-related apoptosis inducing ligand (TRAIL) to the 
corresponding receptors (TRAILR-1 and TRAILR-2) led to formation of a death-
inducing signalling complex (DISC) which subsequently activated caspases 8 and 10 
respectively (Medema et al. 1997; Schulze-Osthoff et al. 1998; Rath and Aggarwal 
1999; Boatright and Salvesen 2003; Ghobrial et al. 2005; Johnstone et al. 2008). 
1.2.2(b) Intrinsic Apoptotic Pathway: 
Intrinsic apoptotic pathway is also called as mitochondrial-mediated apoptotic 
pathway. It is initiated by various intracellular death signals, including DNA damage, 
exposure to reactive oxygen species (ROS), toxins, hypoxia, radiations and 
hyperthermia. Mitochondria and a family of B-cell lymphoma-2 (Bcl-2) proteins 
significantly control intrinsic apoptosis pathway; mitochondria contain apoptotic 
inducing factor (AIF) with Bcl-2 pro-apoptotic proteins. This decreases the 
permeability of the mitochondrial membrane by co-activity of Bcl-2 family which 
dysregulates some caspases leading to release of cytochrome c, follows by formation 
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of apoptosome complex that activates caspases (9, 3 and 7) and amplifies the 
apoptotic signals (Desagher and Martinou 2000; Boatright and Salvesen 2003; 
Elmore 2007; Inoue et al. 2009). The extrinsic apoptotic pathways also initiate the 
intrinsic apoptotic signalling pathways; that caspase 8 can activate the pro-apoptotic 
protein Bid (Li et al. 1998; Portt et al. 2011). 
Studies had identified 25 different types of Bcl-2 proteins; all had been 
allocated outside the mitochondrial membrane. The Bcl-2 proteins include some pro-
apoptotic proteins (such as Bax, Bak, Bid, Bcl-10, Bad, Bim, Bik, and Blk) and other 
anti-apoptotic proteins (such as Bcl-2, Bcl-W, BclX, Bcl-XL, Bcl-XS, BAG) 
(Elmore 2007). 
The Bcl-2 proteins are sub-grouped into three main subsets depending on their 
functions and Bcl-2 homology (BH) domains. The first group is characterized by the 
presence of only a single Bcl-2 homology-3 domain (BH-3 only). It includes Bad, 
Bim, Bid, Bmf, Noxa and Puma. The second group has multiple Bcl-2 homology 
(BH) domains; it includes Bax, Bak and Bok proteins. The third group characterized 
by presence of all four BH domains (multiple BH domains), it includes Bcl-2, Bcl-
W, Bfl-1, Bcl-XL and Mcl-1 proteins (Petros et al. 2004; Ashkenazi 2008; Kang and 
Reynolds 2009). 
Down-regulation of the pro-apoptotic Bcl-2 family proteins or overexpression 
of anti-apoptotic Bcl-2 family members might be resulted with chemotherapy 
resistance in many human cancers, so that it requires the use of combination of anti-
cancer agents (Kang and Reynolds 2009). 
There are some proteins inactivating the mitochondrial pathway comprising of 
inhibitors of apoptosis proteins (IAPs), which include x-linked mammalian inhibitor 
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of apoptosis protein (xIAP), cellular inhibitor of apoptosis (cIAP), livin and survivin 
(Elmore 2007; LaCasse et al. 2008; He et al. 2014). 
Epithelial cell proliferation and differentiation are regulated by various 
factors, including growth hormone (GH) and insulin-like growth factors (IGF-I and 
IGF-II). IGFs are polypeptides that have potent mitogenic effects on breast cancer 
cells. The availability and actions of IGFs are controlled by six high-affinity binding 
proteins (IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6) and their 
proteases in various cells including breast cancer and lung cancer (Coutts et al. 1994; 
Mol et al. 1997; Dziadziuszko et al. 2008). 
Derailment of excretion and expression of GH and IGF may guide to an 
uncontrolled proliferation of the mammary gland; this might cause growth of benign 
or malignant tumours (Arteaga and Osborne 1989; Mol et al. 1997). IGF-I is 
expressed by breast fibroblast; it is overexpressed in breast cancer cells via 
stimulation of IGF type I somatomedin receptor (IGF-1SR). Blockade of this 
receptor is an important strategy for counteracting human cancer (Arteaga and 
Osborne 1989; Mizukami et al. 1990). 
IGF-II has a greater binding potential to various receptors than IGF-I, which 
is related to a wide range of biologic functions of IGF-II. Although some research 
studies had reported that IGF-II possesses potent anti-apoptotic efficiency towards 
many neoplastic cell types, the function of IGF-II was not completely understood. 
The overexpression of IGF-II is related to various but not all cancers, where it has 
shown a regulation of about 50% only of lung cancer cases. IGF-II has no relation 
with increased risk of some other lung cancer cases (Takanami et al. 1996; Rozen et 
al. 1997; Moorehead et al. 2003; Dziadziuszko et al. 2008). 
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The expression of IGFBPs modulates the effects of IGF on cancer cells, in 
which they may stimulate or inhibit the effect of IGFs (Ritvos et al. 1988; Blum et al. 
1989; Owens et al. 1993). IGFBP-3 is considered as the dominant IGFBP in serum 
for circulation of IGF-I; it maintains and prolongs the blood circulation of IGF-I. So 
that, deregulation of IGFBP-3 renders the carcinogenic effect of IGF-I (Figueroa and 
Yee 1992; Perks and Holly 2000). It had been reported that IGFBP-1 may act as a 
negative modulator of IGF-I by blocking of IGF binding to its receptors, leading to 
reduction of the proliferation of cancer cells (Figueroa and Yee 1992; Perks and 
Holly 2000). Several studies had reported inhibitory effects of the identical proteins 
IGFBP-2 and IGFBP-4 on cell growth (Clemmons 1992; Figueroa and Yee 1992). 
Despite structural similarity of IGFBP-3 and IGFBP-5, some studies revealed that 
overexpression of IGFBP-5 inhibited cell proliferation and antagonized the anti-
apoptotic potential of IGF-I (Clemmons 1992; Rozen et al. 1997). 
IGFBP-6 has a special binding affinity to IGF-II. It inhibits prognosis of 
various IGF-II-dependent cancers (Bach 2005). Some studies reported 
overexpression of IGFBP-6 in various cancer cells, including lung cancer (Wegmann 
et al. 1993; Van Doorn et al. 1999). 
The underlying mechanism of IGFs and IGFBPs is complicated and still not 
completely understood. There are some other factors, suggested to influence the 
production and activity of IGFs. Various research studies had shown that some of 
these proteins revealed bifunctional effects (Clemmons 1992; Perks and Holly 2000). 
Reactive oxygen species (ROS) (such as OH- and NO) participate in 
controlling apoptotic mechanism and regulating angiogenesis cascades (Watson et al. 
1997; Wedi et al. 1999; Simon et al. 2000). Higher cell content of ROS inhibits the 
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mitochondrial apoptotic processes (Simon et al. 2000). NO induces heat shock 
proteins (HSP) which increase the intracellular glutathione content and inhibit 
apoptosis (Arrigo 1998). Extrinsic and intrinsic pathways are also controlled by the 
heat shock proteins (HSP) which including HSP10, 27, 60, 70 and 90. HSP27 
reduces a release of cytochrome c; HSP70 and HSP90 inhibit formation of 
apoptosome complex. Whereas,  HSP10 and HSP60 induce activation of executioner 
caspases (Zhivotovsky and Orrenius 2003). 
Anti-angiogenic agents inhibit endothelial cell proliferation and migration.  
They also induce endothelial and tumour cells apoptosis, that the efficiency of anti-
cancer treatment is augmented by the combination of chemotherapy and 
angiogenesis inhibitors (Folkman 2003). 
1.2.3 Common Signal Transduction Cancer Pathways: 
Cancer cells can modify the surrounding environment to facilitate their 
growth and proliferation, metastasis and invasion; through various mechanisms, 
including increasing or decreasing the expression of some proteins (Hanahan and 
Weinberg 2000). Signal transduction pathways is related to activation of cascades of 
intracellular biochemical reactions that lead to the changing expression level of some 
responsible proteins for communications with the internal or external circumstances 
of cancer cells (Lobbezoo et al. 2003). 
Each pathway begins with ligation of extracellular receptors. The activation of 
receptors is translated into biological action that activates proteins (transcriptional 
factors), followed by its translocation into the nucleus, and binding with specific 
binding sites in the DNA (promoters). This triggers the transcription of mRNAs 
which is translated to proteins (Martin 2003; Eccleston and Dhand 2006). 
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Mutation of oncogenic gene establishes the activation of signal transduction 
elements which simulates a condition of receptor activation permanently even if 
there is no relevant growth factor (Hanahan and Folkman 1996). Many pathways 
were found to be hyper-activated in cancer cells. These pathways include Wnt, 
Notch, Myc/Max and hypoxia pathways (Van Es and Clevers 2005; Soucek et al. 
2008; Galluzzo and Bocchetta 2011; Jiang et al. 2015). On the other hand, tumour 
suppressor genes mutations cause deactivation of some other pathways which are in 
relation with cells proliferation, such as p53 (Ahrendt et al. 2003; Feng et al. 2008). 
Signal transduction modulators (STMs) can target cancer pathways 
selectively for cancer treatments. The STMs play important roles in modulation of 
pathways activities, such as blocking receptors on cell surface, blocking the 
mediators between extracellular signals and the transcriptional factor, deactivating 
binding of the transcriptional factors with some promoters, or reducing the effects of 
some other downstream genes (Lobbezoo et al. 2003). 
In addition, a large number of research studies had been conducted to 
investigate the use of many STM compounds for treatments of cancer, like imatinib 
and trastuzumab which have been approved to be used commercially (Lobbezoo et 
al. 2003; Nassar 2010). 
1.2.3(a) Wnt/β-catenin Signalling Pathway: 
Wingless-Int. (Wnt) signalling pathway is a fundamental pathway that 
participates in cell-cell signalling to control many processes, including gene 
expression, cell behaviour, adhesion and polarity process in normal cells as well as 
cancer cells (Cadigan and Nusse 1997). Wnt signals are controlled by three 
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pathways; Wnt/β-catenin pathway (canonical Wnt pathway), Wnt/Ca
+2
 (non-
canonical Wnt pathway) and Wnt/JNK pathways (Moon et al. 2002). 
Studies revealed mutations of many components of Wnt/β-catenin pathway 
are critical for development of many types of human cancer, such as lung 
adenocarcinoma, colon cancer and breast cancer (Morin et al. 1997; Lin et al. 2000; 
Jiang et al. 2015). Moreover, the protein level of β-catenin was significantly 
upregulated leading to induce expression of stem cell protein Oct-4, accompanied 
with high expression of Wnt pathway and the oncogene cyclin D. This enhanced cell 
proliferation, invasion and colony formation efficiencies. Wnt/β-catenin pathway 
makes complex with TCF/LEF transcriptional factors which controls expression of 
many other oncogenes, including c-Myc, cyclin D1 and matrix metalloproteinase 
genes; which induce angiogenesis as well as carcinogenesis cascades (Dihlmann and 
von Knebel Doeberitz 2005; Gehrke et al. 2009; Jiang et al. 2015). 
Tumour regression can be counteracted by down-regulation of Wnt pathway, 
which plays an important role for cancer treatment (Tetsu and McCormick 1999; 
Jiang et al. 2015). 
1.2.3(b) Notch Signalling Pathway: 
Notch signalling pathway plays a crucial role of various cellular activities, 
such as cell proliferation, differentiation, apoptosis, fate specification, adhesion and 
migration, as well as angiogenesis (Bol s et al. 2007). Signalling cascade is initiated 




In vitro and in vivo research studies revealed that hyper-activation of any 
Notch isoform receptor promoted tumour growth and aggressiveness enhanced 
development of many types of cancer, including lung, pancreas, colon, breast and 
renal cancer (Callahan and Raafat 2001; Collins et al. 2004; Van Es and Clevers 
2005; Wang et al. 2006; Farnie and Clarke 2007; Strizzi et al. 2009; Sun et al. 2009; 
Galluzzo and Bocchetta 2011). 
Blocking of Notch pathway will be useful for cancer treatment; such 
inhibitors of Notch pathway include RNA interference, antisense and monoclonal 
antibodies. Wnt and Notch pathways may work synergistically to increase signalling 
cascades of cancer, so that combining of both Wnt and Notch inhibitors will 
potentiate their anti-cancer efficiency (Nickoloff et al. 2003; Van Es and Clevers 
2005). 
1.2.3(c) p53 Signalling Pathway: 
Mutation of p53 gene is commonly occurred in most cancers, in which p53 is 
suppressed in more than 50% cases of human cancer. There are some other 
mechanisms leading to inactivation of p53 gene but they are not related to intragenic 
mutation. The p53 mutations resulted in activation of some other oncogenes, which 
lead to more aggressive and resistant tumour (Ahrendt et al. 2003; Wang and El-
Deiry 2004). 
The p53 gene induces apoptosis and cell cycle arrest; so that it is called 
guardian of the genome. It controls cell death by regulating two apoptotic pathway 
genes; extrinsic pathway (via regulation of death receptor Fas and DR-5 genes), and 
mitochondrial pathway (via regulation of Bax, Bak and Bid proteins) (Lowe et al. 
1993; Burns and El-Deiry 2003; Nassar 2010). Repairing the defects of the p53 
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protein may play an important role in treating cancer (Campling and el-Deiry 2003; 
Toyooka et al. 2003). 
1.2.3(d) TGF-β Signalling Pathway: 
Transforming growth factor-beta (TGF-β) signalling pathway plays a pivotal 
role in many biological processes, among other in cell growth, differentiation, 
apoptosis and angiogenesis. Over expression of TGF-β inhibits tumour growth and 
development in early stage of cancer, such as lung cancer tumour. It inhibits a group 
of proteins called mothers against decapentaplegic proteins (SMAD). Many other 
studies indicated the negative impacts of TGF-β on tumour growth (Thiery 2002; 
Jeon and Jen 2010; Nassar 2010). 
TGF-β is also known as a double-edged sword. Various studies reported the 
tumour suppressor and oncogenic properties of TGF-β pathway. TGF-β promotes 
tumour metastases and invasiveness by inducing EMT and angiogenesis. The 
mechanism of the dual effects of TGF-β, however is still ambiguous (Akhurst and 
Derynck 2001; Akhurst 2002; Sánchez-Capelo 2005; Jeon and Jen 2010; Toonkel et 
al. 2010). 
There are many approaches for developing effective therapies for lung cancer 
via inducing of hyper-expression TGF-β signalling pathway (Thiery 2002; Jeon and 
Jen 2010). 
1.2.3(e) Cell Cycle (pRB/ E2F) Signalling Pathway: 
Retinoblastoma tumour suppressor (pRB) has a critical contribution in cell 
cycle and apoptosis processes. Mutation of the pRB gene has been detected in about 
50% of all human tumours (Yamasaki 2003; Baldi et al. 2011). Heredity is 
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responsible for more than 40% of clinical detected cancer cases due to mutation of 
pRB gene. The effect of pRB gene mutation is detected using DNA cloning 
techniques in many types of cancers, including breast, lung, prostate and leukaemia 
(Weinberg 1991; Draper et al. 1992; Baldi et al. 2011). 
In vitro studies found that introducing pRB protein into cancer cells had 
resulted in inhibition of cell proliferation and cell cycle (Bandara and La Thangue 
1991). Activation of the pRB signalling pathway through a binding of the pRB 
protein with a various transcriptional factors (E2F is the most important one) and a 
binding of active dimers with corresponding promoters that activate the expression of 
many other vital genes, and responsible for cell death process including c-Myc, N-
Myc, thymidylate synthase, cdc2, kinase, cyclin A, thymidine, dihydrofolate 
reductase and DNA polymerase (Bandara and La Thangue 1991; Helin and Ed 
1993). 
1.2.3(f) NF-кB Signalling Pathway: 
Nuclear factor-kappaB (NF-κB) signalling pathway suppresses cell death and 
enhances multiple steps in carcinogenesis such as cell growth, proliferation, invasion, 
metastasis and angiogenesis processes. It also regulates immune system and 
inflammatory responses. Studies have identified more than 200 protein targets 
(transcriptional factors) of NF-кB genes, including Rel, Myc, and Cyclin D1-4 
(which play important roles in cell cycle regulation); Bcl-2, Bcl-XL, A1/Bf-1 (which 
involve in apoptosis cascades); VEGF gene (which plays a key role in angiogenesis 
process); and urokinase plasminogen activator (which participates in regulation of 
cell metastasis processes (Pahl 1999; Chen et al. 2011). 
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Activation of NF-кB protects tumour cells from apoptosis (Barkett and 
Gilmore 1999; Tang et al. 2006; Chen et al. 2011). Many research studies have 
shown that targeting of NF-кB pathway using inhibitory agents can be used as a 
promising anti-cancer agents for many cancers, including lung cancer and leukaemia 
(Ka et al. 2003; Tang et al. 2006; Chen et al. 2011). 
1.2.3(g) Myc/Max Signalling Pathway: 
Myc/Max pathway is an oncogene; research data have reported that Myc/Max 
pathway is overexpressed in more than 70% of all human cancers. Myc oncogene 
family includes c-Myc, N-Myc and L-Myc encode a group of nuclear 
phosphoproteins which regulate cell growth (Zajac-Kaye 2001; Nilsson and 
Cleveland 2003). The Myc/Max pathway plays a very important role in various cell 
cycle process and angiogenesis. Myc is dimerized with its partner protein (Max), 
then, bounded to DNA to exhibit the biological effects. Diminution of this protein 
reduces cell proliferation and duplication (Heikkila et al. 1987; Evan et al. 1992; 
Pelengaris et al. 1999; Rudin and Poirier 2014). 
Targeting of Myc/Max pathway by down-streaming its expression is an 
effective and tumour-specific cancer therapy (Soucek et al. 2008; Romero et al. 
2014). 
1.2.3(h) MAPK Signalling Pathways: 
There are three sub-groups of mitogen activated protein kinases (MAPKs), 
including the extracellular signal regulated enzyme kinases (MAPK/ERK), c-Jun 
amino terminal kinase (MAPK/JNK) and p38 MAPKs. MAPK/JNKs and 
MAPK/ERKs participate in regulation of cell cycle, mitosis, apoptosis and migration. 
